Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

Kenneth Fife, Cosette M. Wheeler, Laura A. Koutsky, Eliav Barr, Darron Brown, Melissa A. Schiff, Nancy B. Kiviat, Kathrin U. Jansen, Harriet Barber, Judith F. Smith, Amha Tadesse, Katherine Giacoletti, Paula R. Smith, Gretchen Suhr, Daniel A. Johnson

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Two candidate vaccines to prevent infection with human papillomavirus (HPV) Types 11 and 16 were studied in similar double-blind, placebo-controlled, dose-escalation trials. L1 virus-like particle (VLP) vaccines were made from recombinant L1 capsid protein of HPV11 or HPV16. Participants received 10, 20, 50, or 100 μg of HPV11 L1 VLPs, 10, 40, or 80 μg of HPV16 L1 VLPs, or placebo at Months 0, 2, and 6. Serum geometric mean antibody levels at Month 7 were 258, 644, 647, and 1112 milli-Merck units (mMU)/ml for the 10, 20, 50, and 100 μg doses of the HPV11 L1 VLP vaccine, respectively, and 479, 808, and 732 mMU/ml for the 10, 40, and 80 μg doses of the HPV16 L1 VLP vaccine, respectively. Antibody to HPV11 and 16 was still present at Month 36 in 96.8 and 93.5% of vaccinees, respectively. Both vaccines were well tolerated and were associated with only mild to moderate injection-site reactions.

Original languageEnglish
Pages (from-to)2943-2952
Number of pages10
JournalVaccine
Volume22
Issue number21-22
DOIs
StatePublished - Jul 29 2004

Fingerprint

Virus-Like Particle Vaccines
virus-like particle vaccines
Human papillomavirus 11
Papillomaviridae
immune response
Safety
placebos
Vaccines
dosage
Placebos
vaccines
antibodies
Human papillomavirus 16
Antibodies
injection site
Capsid Proteins
coat proteins
Injections
Infection
Serum

Keywords

  • Cervical intraepithelial neoplasia
  • Condyloma acuminata
  • Controlled trials
  • Viral vaccines

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. / Fife, Kenneth; Wheeler, Cosette M.; Koutsky, Laura A.; Barr, Eliav; Brown, Darron; Schiff, Melissa A.; Kiviat, Nancy B.; Jansen, Kathrin U.; Barber, Harriet; Smith, Judith F.; Tadesse, Amha; Giacoletti, Katherine; Smith, Paula R.; Suhr, Gretchen; Johnson, Daniel A.

In: Vaccine, Vol. 22, No. 21-22, 29.07.2004, p. 2943-2952.

Research output: Contribution to journalArticle

Fife, K, Wheeler, CM, Koutsky, LA, Barr, E, Brown, D, Schiff, MA, Kiviat, NB, Jansen, KU, Barber, H, Smith, JF, Tadesse, A, Giacoletti, K, Smith, PR, Suhr, G & Johnson, DA 2004, 'Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women', Vaccine, vol. 22, no. 21-22, pp. 2943-2952. https://doi.org/10.1016/j.vaccine.2003.11.058
Fife, Kenneth ; Wheeler, Cosette M. ; Koutsky, Laura A. ; Barr, Eliav ; Brown, Darron ; Schiff, Melissa A. ; Kiviat, Nancy B. ; Jansen, Kathrin U. ; Barber, Harriet ; Smith, Judith F. ; Tadesse, Amha ; Giacoletti, Katherine ; Smith, Paula R. ; Suhr, Gretchen ; Johnson, Daniel A. / Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. In: Vaccine. 2004 ; Vol. 22, No. 21-22. pp. 2943-2952.
@article{2affceae21944357bf5632bdc030d0e8,
title = "Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women",
abstract = "Two candidate vaccines to prevent infection with human papillomavirus (HPV) Types 11 and 16 were studied in similar double-blind, placebo-controlled, dose-escalation trials. L1 virus-like particle (VLP) vaccines were made from recombinant L1 capsid protein of HPV11 or HPV16. Participants received 10, 20, 50, or 100 μg of HPV11 L1 VLPs, 10, 40, or 80 μg of HPV16 L1 VLPs, or placebo at Months 0, 2, and 6. Serum geometric mean antibody levels at Month 7 were 258, 644, 647, and 1112 milli-Merck units (mMU)/ml for the 10, 20, 50, and 100 μg doses of the HPV11 L1 VLP vaccine, respectively, and 479, 808, and 732 mMU/ml for the 10, 40, and 80 μg doses of the HPV16 L1 VLP vaccine, respectively. Antibody to HPV11 and 16 was still present at Month 36 in 96.8 and 93.5{\%} of vaccinees, respectively. Both vaccines were well tolerated and were associated with only mild to moderate injection-site reactions.",
keywords = "Cervical intraepithelial neoplasia, Condyloma acuminata, Controlled trials, Viral vaccines",
author = "Kenneth Fife and Wheeler, {Cosette M.} and Koutsky, {Laura A.} and Eliav Barr and Darron Brown and Schiff, {Melissa A.} and Kiviat, {Nancy B.} and Jansen, {Kathrin U.} and Harriet Barber and Smith, {Judith F.} and Amha Tadesse and Katherine Giacoletti and Smith, {Paula R.} and Gretchen Suhr and Johnson, {Daniel A.}",
year = "2004",
month = "7",
day = "29",
doi = "10.1016/j.vaccine.2003.11.058",
language = "English",
volume = "22",
pages = "2943--2952",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "21-22",

}

TY - JOUR

T1 - Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

AU - Fife, Kenneth

AU - Wheeler, Cosette M.

AU - Koutsky, Laura A.

AU - Barr, Eliav

AU - Brown, Darron

AU - Schiff, Melissa A.

AU - Kiviat, Nancy B.

AU - Jansen, Kathrin U.

AU - Barber, Harriet

AU - Smith, Judith F.

AU - Tadesse, Amha

AU - Giacoletti, Katherine

AU - Smith, Paula R.

AU - Suhr, Gretchen

AU - Johnson, Daniel A.

PY - 2004/7/29

Y1 - 2004/7/29

N2 - Two candidate vaccines to prevent infection with human papillomavirus (HPV) Types 11 and 16 were studied in similar double-blind, placebo-controlled, dose-escalation trials. L1 virus-like particle (VLP) vaccines were made from recombinant L1 capsid protein of HPV11 or HPV16. Participants received 10, 20, 50, or 100 μg of HPV11 L1 VLPs, 10, 40, or 80 μg of HPV16 L1 VLPs, or placebo at Months 0, 2, and 6. Serum geometric mean antibody levels at Month 7 were 258, 644, 647, and 1112 milli-Merck units (mMU)/ml for the 10, 20, 50, and 100 μg doses of the HPV11 L1 VLP vaccine, respectively, and 479, 808, and 732 mMU/ml for the 10, 40, and 80 μg doses of the HPV16 L1 VLP vaccine, respectively. Antibody to HPV11 and 16 was still present at Month 36 in 96.8 and 93.5% of vaccinees, respectively. Both vaccines were well tolerated and were associated with only mild to moderate injection-site reactions.

AB - Two candidate vaccines to prevent infection with human papillomavirus (HPV) Types 11 and 16 were studied in similar double-blind, placebo-controlled, dose-escalation trials. L1 virus-like particle (VLP) vaccines were made from recombinant L1 capsid protein of HPV11 or HPV16. Participants received 10, 20, 50, or 100 μg of HPV11 L1 VLPs, 10, 40, or 80 μg of HPV16 L1 VLPs, or placebo at Months 0, 2, and 6. Serum geometric mean antibody levels at Month 7 were 258, 644, 647, and 1112 milli-Merck units (mMU)/ml for the 10, 20, 50, and 100 μg doses of the HPV11 L1 VLP vaccine, respectively, and 479, 808, and 732 mMU/ml for the 10, 40, and 80 μg doses of the HPV16 L1 VLP vaccine, respectively. Antibody to HPV11 and 16 was still present at Month 36 in 96.8 and 93.5% of vaccinees, respectively. Both vaccines were well tolerated and were associated with only mild to moderate injection-site reactions.

KW - Cervical intraepithelial neoplasia

KW - Condyloma acuminata

KW - Controlled trials

KW - Viral vaccines

UR - http://www.scopus.com/inward/record.url?scp=3142604951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142604951&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2003.11.058

DO - 10.1016/j.vaccine.2003.11.058

M3 - Article

VL - 22

SP - 2943

EP - 2952

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 21-22

ER -